Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11866
Date Received: 28/08/2026
Summary:
Request in relation to communication records.
Date of Response: 31/08/2026
View Response: 11866.pdf
Freedom of Information Request Reference: 11847
Date Received: 20/08/2026
Summary:
Request in relation to personal information.
Date of Response: 21/08/2026
View Response: 11847.pdf
Freedom of Information Request Reference: 11800
Date Received: 03/08/2026
Summary:
Q1. How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib • Nemolizumab Q 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department • Abrocitinib • Baricitinib • Dupilumab • Lebrikizumab • Tralokinumab • Upadacitinib • Nemolizumab *Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen Q3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • 6 months to 5 • Age 6-11 • Age 12-17 • Age 18 and above Q4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products: • Dupilumab • Nemolizumab
Date of Response: 31/08/2026
View Response: 11800.pdf
Freedom of Information Request Reference: 11798
Date Received: 03/08/2026
Summary:
• Spend on Insourcing from May 2026-end of July 2026, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic
Date of Response: 31/08/2026
View Response: 11798.pdf
Freedom of Information Request Reference: 11797
Date Received: 03/08/2026
Summary:
Please could I request data regarding patient initiations on all Scottish Medicines Consortium (SMC) approved biologic therapies for severe asthma. Specifically, please could you provide the total number of patients initiated on the following respiratory biologic medications, broken down by month for the time period of Jan-24 to Jul-26. Benralizumab (Fasenra) Dupilumab (Dupixent) Mepolizumab (Nucala) Omalizumab (Xolair / Omlyclo) Tezepelumab (Tezspire)
Date of Response: 31/08/2026
View Response: 11797.pdf
Freedom of Information Request Reference: 11796
Date Received: 03/08/2026
Summary:
To ask how many health board staff currently are listed as having their main residence outside Scotland. Could you disclose how many employees have their address in England, Wales or Northern Ireland. In addition, if any staff live mainly outside of the UK, could you please disclose the country of their residence. Finally, if you hold the information, could you state how many staff lived outside of Scotland in the following years: 2025/26 2024/25 2023/24
Date of Response: 28/08/2026
View Response: 11796.pdf
Freedom of Information Request Reference: 11795
Date Received: 03/08/2026
Summary:
In the period 1st May 2026 to 31st July 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name   In the period 1st May 2026 to 31st July 2026 please provide a breakdown of: • Total trust spend with off-framework agencies for locums doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name   In the period 1st May 2026 to 31st July 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum doctors for the period 1st May 2026 to 31st July 2026 Please confirm the name of the framework used for the supply of locum doctors in your trust.
Date of Response: 31/08/2026
View Response: 11795.pdf
Freedom of Information Request Reference: 11794
Date Received: 24/07/2026
Summary:
The links to the following guidelines below are shown on the Hypertension & Lipid Services landing page https://apps.nhslothian.scot/refhelp/guidelines/hypertensionandlipidservices/ However they appear to be on an intranet system, rather than the publicly available one, I wonder if you would be kind enough to send me a copy of each? https://apps.nhslothian.scot/refhelp/approach-to-statin-associated-adverse-effects/ https://apps.nhslothian.scot/refhelp/1-assessment/ https://apps.nhslothian.scot/refhelp/faqs/ https://apps.nhslothian.scot/refhelp/lipid-lowering-medication-in-specific-patient-groups/ https://apps.nhslothian.scot/refhelp/lipids/ https://apps.nhslothian.scot/refhelp/suspected-inherited-lipid-disorders-including-familial-hypercholesterolaemia/
Date of Response: 24/08/2026
View Response: 11794.pdf
Freedom of Information Request Reference: 11793
Date Received: 03/08/2026
Summary:
1. Please provide a copy of every current document that records a standard rate your board pays for ad hoc consultant-grade work or on-call cover outside the programmed activities of a substantive job plan. Please include arrangements known as staff bank, medical bank, internal locum, extra-contractual work, additional hours at a separate or locally enhanced rate, waiting-list or additional activity work, or any other alternative payment arrangement - the label does not matter. I am not asking for agency invoices, ordinary extra programmed activities paid at the national contractual rate, or individual payment records. 2. Where a rate covered by item 1 is not fully stated in those documents, please provide the recorded rate from wherever it is held. For each rate, please state: the grade it applies to, your board's own day and time categories, any speciality or site restriction, the payment mechanism, whether an annual leave supplement is included, and the date it took effect. If your board has no standard rate, please say so and provide any recorded formula, default, minimum, maximum or approval limit used instead. 3. Please provide the recorded rules on whether a doctor or dentist holding a substantive post with your board may also register for, work, and be paid for ad hoc consultant-grade shifts for the same board, under any of the mechanisms in item 1. Please include the relevant policy, bank terms, contract terms or approval procedure. If prior approval is needed, please say which role approves and on what conditions. If no document answers the question directly, please provide the recorded terms your board would use to decide. 4. For the rates you provide, please give: (a) the date each took effect, (b) the date and outcome of the most recent review of them, including a review that changed nothing, and (c) any replacement rate already approved but not yet in force, with its planned start date. I am not asking for anything created after you receive this request.
Date of Response: 28/08/2026
View Response: 11793.pdf
Freedom of Information Request Reference: 11792
Date Received: 03/08/2026
Summary:
I understand that a team of consultants were tasked with assessing the cladding on the new Royal Hospital for Children and Young People in the wake of the Grenfell Tower disaster. Can I get a copy of their final report which was submitted to NHS Lothian health board please? I think this was submitted to the board in or around January 2022. can I also ask whether the 3% daylight factor required by the contract for the childrens bedrooms was achieved for any of the 4 bedroom wards in the Royal Hospital for Children and Young People?
Date of Response: 28/08/2026
View Response: 11792.pdf
Freedom of Information Request Reference: 11791
Date Received: 03/08/2026
Summary:
Regarding the job banding and grading of the Resilience Head role within your organisation. Please provide the following information: 1. The current job band/grade assigned to the Resilience Head role. 2. The date on which the current banding or grading decision was made and how this compares to neighbouring NHS boards with the equivalent role. 3. The job evaluation or grading framework used to determine the role’s banding 4. A copy of the role profile/job description used for the evaluation (with any appropriate redactions applied if required). 5. The factors, criteria, or scoring outcomes that informed the banding decision. 6. Details of any review, reassessment, or challenge of the role’s banding since it was established.
Date of Response: 28/08/2026
View Response: 11791.pdf
Freedom of Information Request Reference: 11790
Date Received: 03/08/2026
Summary:
To ask what the total energy bill for your health board was in the following financial years. If possible, could this be broken down by gas and electricity. 2021/22 2022/23 2023/24 2024/25 2025/26
Date of Response: 31/08/2026
View Response: 11790.pdf
Freedom of Information Request Reference: 11789
Date Received: 31/07/2026
Summary:
1. Existing Aquariums Please confirm whether the Trust currently owns or operates any ornamental aquarium(s) or aquatic displays. If yes, please provide: The number of aquariums currently in operation. Their general location (e.g. reception, children's ward, outpatient department, waiting area). The approximate year each aquarium was installed. 2. Installation Supplier For each aquarium, please provide: The company that supplied and/or installed the aquarium. Whether the installation was procured via a tender or procurement framework or a direct award (and, if applicable, the name of the framework). 3. Maintenance Please confirm: Whether aquarium maintenance is carried out in-house or by an external contractor. If externally maintained: Name of the contractor. Contract start date. Contract expiry or renewal date. Approximate annual contract value. 4. Future Projects Please confirm whether the Trust currently has any plans, approved projects or budget allocations for new aquarium installations, replacements or refurbishments within the next 24 months. 5. Procurement Please provide: The department responsible for procuring aquarium installations and maintenance. The job title of the person or team responsible. 6. Expenditure Please provide, where available: Total expenditure on aquarium installations over the previous five financial years. Annual expenditure on aquarium maintenance for each of the previous five financial years. 7. Supporting Documentation Please provide copies of any business cases, reports, evaluations or studies relating to the installation of aquariums, including any documents discussing patient wellbeing, staff wellbeing, visitor experience or therapeutic benefits.
Date of Response: 28/08/2026
View Response: 11789.pdf
Freedom of Information Request Reference: 11786
Date Received: 30/07/2026
Summary:
I am interested in work about NHS finances carried out for the Scotland East region. Please provide all papers, meeting minutes and other documents covering the Scotland East region’s finances. This would include but is not limited to modelling, financial outlook, options for savings, papers presented at meetings, minutes and agendas, etc.
Date of Response: 28/08/2026
View Response: 11786.pdf
Freedom of Information Request Reference: 11783
Date Received: 29/07/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 1.1 Benralizumab (Fasenra) 1.2 Depemokimab (Exdensur) 1.3 Dupilumab (Dupixent) 1.4 Mepolizumab (Nucala) 1.5 Omalizumab (Xolair) 1.6 Reslizumab (Cinqaero) 1.7 Tezepelumab (Tezspire) Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 2.1 Benralizumab (Fasenra) 2.2 Depemokimab (Exdensur) 2.3 Dupilumab (Dupixent) 2.4 Mepolizumab (Nucala) 2.5 Omalizumab (Xolair) 2.6 Reslizumab (Cinqaero) 2.7 Tezepelumab (Tezspire) Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 3.1 Dupilumab (Dupixent) Q4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 4.1 Benralizumab (Fasenra) 4.2 Depemokimab (Exdensur) 4.3 Dupilumab (Dupixent) 4.4 Mepolizumab (Nucala) 4.5 Omalizumab (Xolair) 4.6 Reslizumab (Cinqaero) 4.7 Tezepelumab (Tezspire)
Date of Response: 27/08/2026
View Response: 11783.pdf
Freedom of Information Request Reference: 11782
Date Received: 29/07/2026
Summary:
Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab Q2. How many patients were treated by the Gastroenterology Department or Clinic with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab Q3. How many patients with Crohn’s Disease, Ulcerative Colitis or Inflammatory Bowel Disease NOS in total regardless of department / clinic, were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab
Date of Response: 27/08/2026
View Response: 11782.pdf
Freedom of Information Request Reference: 11781
Date Received: 29/07/2026
Summary:
Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Abrocitinib Apremilast Baricitinib Bimekizumab Brodalumab Certolizumab Pegol Deucravacitinib Dupilumab Etanercept Guselkumab Infliximab Ixekizumab Lebrikizumab Nemolizumab Risankizumab Secukinumab Tildrakizumab Tralokinumab Ustekinumab Q2. How many patients were treated by the Dermatology or Rheumatology Departments or Clinics with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Apremilast Baricitinib Bimekizumab Brodalumab Certolizumab Pegol Etanercept Guselkumab Infliximab Ixekizumab Risankizumab Secukinumab Ustekinumab Q3. How many patients with Plaque Psoriasis or Psoriatic Arthritis across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Bimekizumab Secukinumab Apremilast Certolizumab Pegol Etanercept Guselkumab Infliximab Ixekizumab Risankizumab Ustekinumab Brodalumab Deucravacitinib Q4. How many patients with Atopic Dermatitis across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Baricitinib Dupilumab Nemolizumab Q5. How many patients with Hidradenitis Suppurativa across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Bimekizumab Secukinumab
Date of Response: 27/08/2026
View Response: 11781.pdf
Freedom of Information Request Reference: 11780
Date Received: 29/07/2026
Summary:
1. Please provide me with a breakdown of how many patients came into the walk in centre in your board area and registered as a ‘case’ each day since the centre opened. 2. Please confirm if there have been any days, since the centre opened, where no patients have come in and how many days this has happened.
Date of Response: 24/08/2026
View Response: 11780.pdf
Freedom of Information Request Reference: 11779
Date Received: 29/07/2026
Summary:
I am writing to formally request an internal review of the decision regarding FOI request 11643. In your response dated 28 July 2026, the Board claimed it does not hold administrative email addresses for GP practices, stating it only communicates via "individuals or clinical mailboxes". I am challenging the assertion that administrative contact information is "not held" and the subsequent blanket withholding of this data. While I acknowledge that clinical mailboxes used solely for patient data should not be disclosed, the Board inevitably uses electronic endpoints to communicate operationally with independent GP contractors (e.g., sending contract updates, public health directives, and administrative notices). If the Board routes this administrative communication to the direct email addresses of Practice Managers (the "individuals" mentioned in your response), then those endpoints function as the main administrative contacts and fall squarely within the scope of my request. If the Board considers a Practice Manager's email address to be exempt personal data under Section 38(1)(b) of FOISA because it contains their name, the correct legal procedure is not to issue a blanket refusal or claim the data is "not held." Instead, the Board has a duty to redact the identifying elements of the email string (e.g., providing [Redacted]@nhslothian.scot.nhs.uk) to disclose the functional administrative routing information while protecting the individual's identity. Practice Managers are senior administrative officials managing publicly funded contracts; their official business contact routes carry a low expectation of absolute privacy when balanced against the public interest of transparency. I request that you conduct a thorough internal review, identify the electronic endpoints used for non-clinical, operational communication with these practices, and release them, applying redactions to purely personal identifiers where strictly necessary.
Date of Response: 31/08/2026
View Response: 11779.pdf
Freedom of Information Request Reference: 11776
Date Received: 27/07/2026
Summary:
1) How many complaints have NHS Lothian received against the Western General Hospital regarding the treatment provided by Mammographer's for the years 2023 to 26 itemised for each year. 2) How many complaints have NHS Lothian received against the mobile units within NHS Lothian regarding the treatment provided by Mammographer's for the years 2023 to 26 itemised for each year. 3) How many complaints have NHS Lothian received against Ardmillan House regarding the treatment provided by Mammographer's for the years 2023 to 26 itemised for each year.
Date of Response: 24/08/2026
View Response: 11776.pdf
Freedom of Information Request Reference: 11775
Date Received: 29/07/2026
Summary:
• In year 25/26, how many hours were lost / given in Lothian to Paternity Leave? (Also known as "New parent support leave") [outlined in section 15.0 AfC} • In year 25/26, how many hours were lost / given in Lothian to Maternity Leave? Additionally: • How many staff as a % of the workforce, identify as Male? • How many staff as a % of the workforce, identify as Female?
Date of Response: 28/08/2026
View Response: 11775.pdf
Freedom of Information Request Reference: 11774
Date Received: 28/07/2026
Summary:
1. Does the argument that it’s not “clinically safe” simply mean that there aren’t enough WTE consultants? 2. How many WTE consultants are required for treatment to be “clinically safe”? 3. The July 5th minute says that “recruitment continues”. What was the result of that recruitment? 4. Why has there been no additional recruitment? 5. Who decided that there should be no additional recruitment? 6. When was that decision last made? 7. I asked about approval by Lothian Health Board, not the Executive Leadership Team. Has this continuing non-treatment been approved by the Board? If so, when?
Date of Response: 27/08/2026
View Response: 11774.pdf
Freedom of Information Request Reference: 11773
Date Received: 28/07/2026
Summary:
What is the GP to patient ratio in Craiglockhart medical group please?
Date of Response: 25/08/2026
View Response: 11773.pdf
Freedom of Information Request Reference: 11771
Date Received: 27/07/2026
Summary:
I would be grateful if you could provide the following information regarding the NHS Lothian Adult ADHD Service: What month and year of adult ADHD diagnoses are currently being invited to begin medication titration? How many patients are currently waiting to start ADHD medication titration? What is the current median waiting time from diagnosis to the first titration appointment? What is the longest current wait from diagnosis to the first titration appointment? How many clinicians are currently authorised to prescribe and supervise ADHD medication titration within the adult service? If available, what is the estimated waiting time for a person diagnosed today to begin medication titration?
Date of Response: 25/08/2026
View Response: 11771.pdf
Freedom of Information Request Reference: 11770
Date Received: 27/07/2026
Summary:
Part A. General practice workforce vacancies 1. For each GP practice in your Board area, the number of vacant GP posts (headcount and whole-time equivalent) as at the most recent date for which information is held, and, where recorded, how long each post has been vacant. 2. If practice-level vacancy information is not held, any aggregate assessment of GP workforce vacancies across the Board area produced in the last 12 months, for example workforce planning reports or primary care strategy papers. Part B. Patient list closures and capacity 3. The number of applications or notifications from GP practices relating to closure of their patient lists, whether formal or informal (including managed or temporary closures and agreed restrictions on new registrations), received in each of the financial years 2024/25 and 2025/26 to date, and for each one the practice name, the date received, and the outcome (approved, refused, withdrawn, or agreed). 4. For each of the same financial years, the number of GP practices in your area that closed, merged, or terminated their General Medical Services contract, with the practice name and effective date in each case. 5. Any register or list currently maintained by the Board of practices whose patient lists are formally closed, or subject to agreed restrictions on new patient registrations, as at the date of this request. 6. Any list currently maintained by the Board of practices identified as requiring support with capacity or sustainability, for example through a primary care risk register or sustainability programme, as at the date of this request. If disclosing practice names would engage an exemption, please provide the information with practice identifiers redacted rather than refusing the item in full.
Date of Response: 25/08/2026
View Response: 11770.pdf
Freedom of Information Request Reference: 11769
Date Received: 27/07/2026
Summary:
Q1. How many total patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Dravet Syndrome (DS) Q2. Of total DS patients, how many have been treated with Epidyolex (Cannabidiol) in the last 12 months? Q3. Of total DS patients, how many have been treated with Fintepla (Fenfluramine) in the last 12 months? Q4. How many total patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Lennox-Gasteau Syndrome (LGS) Q5. Of total LGS patients, how many have been treated with Epidyolex (Cannabidiol) in the last 12 months? Q6. Of total LGS patients, how many have been treated with Fintepla (Fenfluramine) in the last 12 months? Q7. How many adult (aged 18+) patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Dravet Syndrome (DS) Q8. How many adult (aged 18+) patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Lennox-Gasteau Syndrome (LGS)
Date of Response: 27/08/2026
View Response: 11769.pdf
Freedom of Information Request Reference: 11768
Date Received: 27/07/2026
Summary:
I am writing to seek clarification regarding NHS Lothian's policy on wearing staff uniforms while travelling on public transport. Could you please advise whether staff are permitted to wear their uniform when commuting to and from work on public transport, and whether there are any specific guidelines or infection prevention requirements that should be followed? I would be grateful for any information or relevant policy documents you can provide.
Date of Response: 24/08/2026
View Response: 11768.pdf
Freedom of Information Request Reference: 11767
Date Received: 27/07/2026
Summary:
For the period 1 January 2023 to the date of this request, please provide: Copies of correspondence, briefings, reports, presentations, meeting records or advice exchanged with the Scottish Government, Healthcare Improvement Scotland, Public Health Scotland or another body concerning: a. the safety or regulation of non-surgical cosmetic procedures; b. restrictions upon which practitioners may perform specified procedures; c. requirements to operate from HIS-registered premises; d. the presence of an authorised prescriber or healthcare professional; and e. procedure classification or risk categorisation. The number of attendances, referrals or admissions recorded by the Board following complications or suspected complications from non-surgical cosmetic procedures, broken down where recorded by: a. financial or calendar year; b. procedure; c. type of complication; d. hospital, service or department; e. whether treatment was provided in Scotland; and f. whether the original procedure was performed in an NHS or private setting. For the records counted under point 2, the number attributed to procedures performed by: a. independent aesthetic practitioners; b. doctors; c. dentists; d. nurses or midwives; e. pharmacists; f. other statutory healthcare professionals; g. practitioners whose professional status was not recorded; and h. practitioners whose identity or status could not be verified. Aggregate figures are requested. No information identifying clients or individual practitioners is required. Copies of any coding guidance, data definitions, collection instructions or methodology used to identify: a. a non-surgical cosmetic procedure; b. a complication arising from such a procedure; c. the procedure performed; d. the setting in which it was performed; and e. the professional or registration status of the person who performed it. Copies of any analysis, audit, research, literature review or internal report comparing complication rates or outcomes between different practitioner or professional groups. Copies of any complication, injury, infection, referral or admission data supplied by the Board to the Scottish Government, HIS, Public Health Scotland, a parliamentary committee, an advisory group or another body for the purpose of developing or supporting the proposed legislation. Copies of requests received by the Board for evidence, data or professional advice concerning the Scottish Government consultation, the relevant Bill, procedure groupings, practitioner restrictions, premises requirements or proposed secondary legislation. Copies of any evidence, advice, recommendations or concerns submitted in response to the requests identified under point 7. Copies of records identifying NHS Board employees or representatives who attended or contributed to any government advisory group, expert group, workshop or meeting concerning the regulation of non-surgical cosmetic procedures. Please provide their job titles, the body or meeting attended and the dates of participation. Copies of any assessment of the expected effect of the legislation upon NHS services, including: a. changes in the number or severity of complications presented to the NHS; b. displacement of procedures into informal or unregulated settings; c. increased demand for corrective treatment; d. reduced reporting of complications; e. treatment availability in rural or island areas; and f. additional costs or staffing requirements for the Board. Copies of records received concerning the number or participation of practising independent aesthetic practitioners directly involved in developing the regulatory proposals, excluding people who only submitted an open public consultation response. Copies of records concerning the role, status, authority or representative standing of: a. the Joint Council for Cosmetic Practitioners; b. Save Face Limited; c. the Scottish Medical Aesthetics Safety Group; d. BABTAC; and e. the British Beauty Council. Copies of any correspondence or meeting records between the Board and an organisation listed in point 12 concerning non-surgical cosmetic procedures, practitioner competence, complication reporting, referrals, public guidance or Scottish regulation.
Date of Response: 25/08/2026
View Response: 11767.pdf
Freedom of Information Request Reference: 11765
Date Received: 27/07/2026
Summary:
Please could you provide the Whole Time Equivalent (WTE) numbers for the following medical staffing categories within your Health Board: 1. Consultants 2. Associate Specialists (or the current equivalent grade under the SAS contract reform) 3. Specialty Doctors 4. Foundation Year 1 (FY1) and Foundation Year 2 (FY2) Doctors (either separately or combined) Please provide this data annually for the years 2022, 2023, 2024, 2025, and 2026.
Date of Response: 28/08/2026
View Response: 11765.pdf
Freedom of Information Request Reference: 11764
Date Received: 24/07/2026
Summary:
Please provide the annual test volumes for your most recent complete reporting period, either Financial Year (e.g. 2025/26) or Calendar Year (2025).
Date of Response: 24/08/2026
View Response: 11764.pdf
Freedom of Information Request Reference: 11763
Date Received: 23/07/2026
Summary:
I am writing to request the recorded information set out below regarding the Trust’s histopathology services. Where any figure is not held in the exact form requested, I would be grateful for the nearest available data together with a note of the basis on which it is provided: 1. What was your total histopathology department case volume for in each of the two most recent completed financial years (FY24/25 and FY25/26) and the % of each which was digital? Please provide the number of final cases (as opposed to slides, blocks or specimens). 2. Of that volume, how many cases were reported in-house versus outsourced to an external provider in each year, and which external provider(s) were used? 3. For outsourced histopathology work, please break down volume and spend according to whether the provider performed the full laboratory process as well as reporting (wet and report), or provided reporting only with the Trust performing all laboratory processing (report only). 4. For each provider used, please confirm the method of case transfer (glass slide delivery or digital transfer). 5. For each provider used, please confirm the method of report delivery (email/PDF, secure reporter access to local pathology system, separate provider portal, electronic automation into local pathology system). 6. What percentage of histopathology cases were reported within 7, 10 and 14 calendar days of receipt over the most recent 12-month period (measured against Royal College of Pathologists key performance indicators)? 7. For outsourced histopathology work, what proportion (by case volume) was sent to each provider as physical glass slides versus as digital whole-slide images? 8. What was the total spend on outsourced histopathology reporting in each of the two most recent completed financial years, broken down by provider? 9. Does the Trust use any insourcing arrangement (a third-party providing reporting or laboratory capacity using the Trust’s own facilities or systems)? If so, please state the provider(s), approximate volume, and spend. 10. What percentage of the Trust’s in-house histopathology reporting is currently reported digitally? Please also state the digital pathology deployment status. 11. As at 20 July 2026, and expressed in whole-time equivalents (WTE), what is the histopathology reporting workforce (including funded establishment, filled posts, vacancies, and locum or agency cover) for consultant histopathologists? 12. For any current outsourced histopathology reporting contract(s): the start and end dates, extension or renewal options, contract value, and the procurement route or framework used.
Date of Response: 21/08/2026
View Response: 11763.pdf
Freedom of Information Request Reference: 11761
Date Received: 24/07/2026
Summary:
Do you provide iron fusions for appropriate patients from other health boards in Scotland ?
Date of Response: 24/08/2026
View Response: 11761.pdf
Freedom of Information Request Reference: 11760
Date Received: 24/07/2026
Summary:
1. Total patients with hereditary angioedema (HAE, ICD-10-CM D84.1) were registered at the institution as of the end of June 2026? 2. How many patients were: a) types 1 b) type 2 c) type 3 (normal C1 inhibitor) 3. How many patients in each age range: a. 45 years 4. How many were: a) male b) female 5. Volume of medication dispensed and/or consumed from January 1st to June 30th, 2026, for each product below. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful. List of Medications: lanadelumab (Takzhyro - SC) pdC1-inhibitor (Cinryze - IV) pdC1-inhibitor (Berinert - IV and SC) rC1-inhibitor (Ruconest - IV) icatibant (Firazyr and generic - SC) berotralstat (Orladeyo cap) sebetralstat (Ekterly cap) garadacimab (Andembry - SC)
Date of Response: 18/08/2026
View Response: 11760.pdf
Freedom of Information Request Reference: 11759
Date Received: 23/07/2026
Summary:
This FOI is in relation to the Scottish Driving Assessment Service. For the 12-month period immediately preceding the date of the request, please provide: 1) The total number of driving assessments completed. 2) The number of assessments where the outcome was that the individual was assessed as: a) fit to continue driving without restriction; b) fit to continue driving subject to recommendations, restrictions or adaptations; c) not fit to continue driving (or recommended to cease driving); and d) any other outcome category used by the Service. 3) If recorded, the percentage represented by each outcome category. 4) If outcome data is recorded using different terminology, please provide the figures using the categories held by the Service together with an explanation of those categories.
Date of Response: 21/08/2026
View Response: 11759.pdf
Freedom of Information Request Reference: 11757
Date Received: 23/07/2026
Summary:
I would be grateful if you could provide the following information regarding your organisation's IT hardware estate and IT asset disposal arrangements. 1. Who is your current IT Asset Disposal (ITAD) provider? 2. When does the current ITAD contract expire? 3. What is the total annual value of the ITAD contract? 4. Was the contract awarded through a procurement framework? If so, please state which framework. 5. Approximately how many desktop PCs are currently in use? 6. Approximately how many laptops are currently in use? 7. Approximately how many tablets are currently in use? 8. Approximately how many mobile phones are currently managed? 9. Approximately how many end-user devices are disposed of each year? 10. What is your standard hardware refresh cycle for desktops and laptops? 11. Is data sanitisation performed internally or by your ITAD provider? 12. Which data erasure software or standard is used (for example, Blancco or NIST 800-88)? 13. During the last completed financial year, approximately what revenue was generated through the resale of redundant IT equipment? 14. If no revenue was generated, please confirm whether retired equipment is recycled, destroyed, or otherwise disposed of. 15. Which department is responsible for managing the ITAD contract? 16. Is your organisation expecting to procure or re-tender IT asset disposal services within the next 24 months?
Date of Response: 25/08/2026
View Response: 11757.pdf
Freedom of Information Request Reference: 11755
Date Received: 23/07/2026
Summary:
I request the following information relating to Diversity, Equity and Inclusion (DEI), Equality, Diversity and Inclusion ( EDI ), or similarly named programmes and activities within your council for the last five financial years. For each financial year, please provide: 1. DEI/ EDI Training Expenditure i.e. how much was spent on external organizations providing DEI training 2. DEI/ EDI Training Content i.e. copies of training materials, presentations, course outlines, learning objectives, handbooks, guidance documents, or other materials used for DEI/ EDI training. 3. DEI/ EDI Staff Positions i.e. list of all roles whose primary responsibility includes DEI, EDI , equality, inclusion, diversity, belonging, positive action, or related functions. Please include an annual salary or salary band.
Date of Response: 27/08/2026
View Response: 11755.pdf
Freedom of Information Request Reference: 11754
Date Received: 22/07/2026
Summary:
I am writing to request information about Mental Health services at your Trust. 1. In the last 12 months (of data), in total how many patients were managed by your Trust for the following conditions a. Schizophrenia (F20) b. Bipolar Disorder (F31) c. Other psychoses (F21-29 inclusive) 2. In the last 12 months (of data), how many patients with Schizophrenia have been treated within each of the following services: a. Early Intervention Psychosis service team b. Acute Services c. Community Mental Health Team 3. In the last 3 months (of data), how many patients with Schizophrenia were treated with each of the following antipsychotic medications a. Risperidone b. Olanzapine c. Quetiapine d. Aripiprazole e. Amisulpride f. Lurasidone g. Paliperidone h. Cariprazine i. Clozapine j. Other treatment 4. In the last 3 months (of data), how many patients with Other Psychoses were treated with each of the following antipsychotic medications a. Risperidone b. Olanzapine c. Quetiapine d. Aripiprazole e. Amisulpride f. Lurasidone g. Paliperidone h. Cariprazine i. Clozapine j. Other treatment 5. In the last 12 months (of data), how many patients with Schizophrenia were discharged to primary care from each of the following services? a. Early Intervention Psychosis service team b. Acute Services/In-patient c. Community Mental Health Team 6. In the last 12 months (of data), how many patients with Schizophrenia were discharged from the Early Intervention Psychosis service team to the Community Mental Health Team
Date of Response: 21/08/2026
View Response: 11754.pdf
Freedom of Information Request Reference: 11753
Date Received: 22/07/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel 1.4 Darolutamide (Nubeqa) 1.5 Docetaxel 1.6 Enzalutamide (Xtandi) 1.7 Lutetium-177 PSMA-617 (Pluvicto) 1.7 Olaparib (Lynparza) 1.8 Relugolix (Orgovyx, Ryeqo) 1.9 Talazoparib (Talzenna) Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi) Q4. How many patients were treated with the following combinations in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) monotherapy 4.3 Olaparib (Lynparza) + Abiraterone Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 5.1 Abiraterone 5.2 Enzalutamide Q6. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between 1st April 2026 to the end of June 2026, or latest 3-month period for which data is available? Q7. How many patients received the following products for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 7.1 Atezolizumab (Tecentriq) 7.2 Cemiplimab (Libtayo) 7.3 Durvalumab (Imfinzi) 7.4 Nivolumab (Opdivo) 7.5 Pembrolizumab (Keytruda) Q8. How many patients received the following products for Non-Small Cell Lung Cancer as Neo-adjuvant or Adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 8.1 Atezolizumab 8.2 Durvalumab 8.3 Nivolumab 8.4 Pembrolizumab 8.5 Durvalumab Q9. How many patients received the following combination or monotherapy for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy 9.2 Cemiplimab monotherapy
Date of Response: 21/08/2026
View Response: 11753.pdf
Freedom of Information Request Reference: 11751
Date Received: 21/07/2026
Summary:
The response provided is factually irreconcilable with a previous executive-signed disclosure issued by the Board. This creates a data integrity failure that undermines the public’s confidence in the Board’s governance. Direct Contradiction: In a response dated 16/06/2026 (Ref: 11597), signed by the Executive Director of Nursing, the Board explicitly confirmed: "Yes [we utilize stapler devices]" and provided specific technical data (e.g., "Dual grip", "15 minutes" for stapler procedures). In the response under review, the Board stated: "Staplers are not used in NHS Lothian’s theatres." Governance Failure: These statements are mutually exclusive. It is not possible for both disclosures to be accurate. As both documents bear the signature of the same Executive Director, this suggests a systemic failure in the Board’s ability to verify the accuracy of clinical information before it is formally released to the public. Requested Resolution: Under the Freedom of Information (Scotland) Act 2002, I request that a senior officer not involved in the original decision conducts an investigation to: Identify which of the two contradictory statements is factually correct. Detail the "mechanism of failure" that allowed the Board to issue two completely different accounts of its own surgical capabilities within a 30-day period. Confirm if the inaccurate disclosure has been reported to the Board’s Information Governance lead for correction. Provide a formal, corrected statement regarding the Board's current policy and usage of stapler-assisted surgical technology.
Date of Response: 25/08/2026
View Response: 11751.pdf
Freedom of Information Request Reference: 11750
Date Received: 14/07/2026
Summary:
1. What’s CMT? 2. The August 2022 note says that the next review was to be on March 31 2023. Can you send me a copy of that (and any more recent reviews)? 3. Has this decision never been discussed or approved by Lothian Health Board? 4. Also, the July 5th minute says this: "three orthodontic consultants (2.2wte out of 3.2wte) have made decisions to either retire or move to other roles / areas, and thus there is an emergent pressure within orthodontics as recruitment continues.” After almost four years, what has been the result of that recruitment?
Date of Response: 28/07/2026
View Response: 11750.pdf
Freedom of Information Request Reference: 11746
Date Received: 20/07/2026
Summary:
Please can you assist with supplying the answers to the below questions: • Number of shifts booked by ON Framework agency staff broken down by provider and month from 1st March 2026 To 30th June 2026 • Number of shifts booked by OFF Framework agency staff broken down by provider and month from 1st March 2026 To 30th June 2026 • Total spend on ON Framework agency staff broken down by agency and month from 1st March 2026 To 30th June 2026 • Total spend on OFF Framework agency staff broken down by agency and month from 1st March 2026 to 30th June 2026 • Where has the health board been utilising the support for agency staffing support the most from 1st March to 30th June 2026, is it in your hospitals, community care or residential care? • Can you provide a total sum of agency expenditure across all areas of healthcare from the 1st of March 2026 - 30th June 2026?
Date of Response: 28/08/2026
View Response: 11746.pdf
Freedom of Information Request Reference: 11745
Date Received: 20/07/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2026 and the end of June 2026, or latest 3-months for which data are available?  1.1 Niraparib (Zejula)  1.2 Rucaparib (Rubraca)  1.3 Olaparib (Lynparza)  1.4 Cemiplimab (Libtayo) 1.5 Mirvetuximab soravtansine (Elahere)  Q2. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?   2.1 Olaparib for all ovarian, fallopian tube or primary peritoneal cancers 2.2 Olaparib + bevacizumab 2.3 Olaparib monotherapy    2.4 Bevacizumab or all ovarian, fallopian tube or primary peritoneal cancers 2.5 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin   2.6 Bevacizumab monotherapy Q3.  How many patients were treated with rucaparib (Rubraca) for the following indications in the 3 months between 1st April 2026 to the end of June 2026 or latest 3-months for which data are available?  3.1 1L advanced ovarian cancer in response to 1L platinum chemotherapy (TA1055)  3.2 Relapsed platinum-sensitive ovarian cancer (TA1007)  Q4. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines in the 3 months between 1st April 2025 to the end of June 2026, or latest 3-months for which data are available?  4.1 Dostarlimab (Jemperli)  4.2 Pembrolizumab (Keytruda)  4.3 Lenvatinib (Lenvima)  4.4 Durvalumab (Imfinzi) Q5. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?  5.1 Dostarlimab monotherapy 5.2 Dostarlimab in combination with Chemotherapy 5.3 Pembrolizumab monotherapy 5.4 Pembrolizumab + Lenvatinib in combination 5.5 Pembrolizumab in combination with Chemotherapy 5.6 Durvalumab with Carboplatin and Paclitaxel 5.7 Durvalumab monotherapy 5.8 Durvalumab + Olaparib combination Q6. How many patients with Endometrial Cancer (C54.1) received the following treatments by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available? 6.1 Dostarlimab + Carboplatin + Paclitaxel 6.2 Pembrolizumab + Carboplatin + Paclitaxel 6.3 Pembrolizumab + Lenvatinib 6.4 Dostarlimab as monotherapy at cycle 1 6.5 Dostarlimab as monotherapy maintenance (cycle 7+) 6.6 Pembrolizumab as monotherapy at cycle 1 6.7 Pembrolizumab as monotherapy maintenance (cycle 7+) Q7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?  7.1 Cutaneous Squamous Cell Carcinoma 7.2 Basal Cell Carcinoma 7.3 Non-small Cell Lung Cancer 7.4 Cervical Cancer Q8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?  8.1 Curative 8.2 Palliative Q9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 
Date of Response: 28/08/2026
View Response: 11745.pdf
Freedom of Information Request Reference: 11743
Date Received: 20/07/2026
Summary:
Please provide the following information about Scottish Brain Sciences BriDGe Study. 1) The current status and progress of the BriDGe study. 2) The anticipated completion date of the study. 3) Copies of the study protocol, governance framework and any published study document that can be disclosed. 4) Details of the NHS Boards currently participating in the study. 5) Whether NHS Lanarkshire has been invited to participate in the study or has expressed an interest. 5) Whether any additional NHS Boards are expected to join the study and, if so, which Boards. 6) Whether discussions have taken place with the Scottish Government or NHS Scotland regarding future implementation of blood biomarker testing for Alzheimer's disease. 7) Whether implementation planning has commenced beyond the research phase. 8) Whether any health economic modelling or cost-effectiveness analysis has been undertaken to date. 9) Whether any interim findings, results or evaluation date have been shared with NHS Scotland. 10) Whether stakeholder engagement has been undertaken with patient and carer organisations. 11) Whether there are plans for wider public or stakeholder consultation regarding future implementation. 12) Copies of any correspondence (emails, letters, meeting notes or reports) with NHS Scotland or other relevant bodies concerning future rollout or implementation, where disclosable. NHS Lothian FAST (Facilitating Access to blood biomarker testing for Alzheimer's disease in memory services) Study. 1) The objectives and scope of the FAST study. 2) The current stage of recruitment/data collection and evaluation. 3) The expected completion date of the study. 4) Whether NHS Lanarkshire has been approached to participate or discuss participation in the study. 5) Whether other NHS Boards have expressed an interest in participating or adopting the pathway. 6) Whether plans are in place for implementation of blood biomarker testing in routine clinical practice following the study. 7) Copies of any implementation reports, evaluation findings or recommendations that can be disclosed. 8) Details of the funding for the FAST Study, including the source(s) of funding and total funding awarded. 9) The cost per participant/test within the study, where available. 10) Whether discussions have taken place with NHS Scotland or the Scottish Government regarding future commissioning or national rollout. 11) Whether the study team anticipates that blood biomarker testing will be used routinely within NHS Scotland in the future, and indicative timescales if available. 12) Whether an equality impact assessment has been undertaken as part of the study. 13) Copies of any correspondence with NHS Scotland or other relevant bodies regarding future uptake and implementation across Scotland, where disclosable.
Date of Response: 25/08/2026
View Response: 11743.pdf
Freedom of Information Request Reference: 11742
Date Received: 20/07/2026
Summary:
I would be very grateful if you could please provide: -The current notional rent assessed for each GP practice within the Board area. -The effective date of each assessment. -The gross internal area (or reimbursable area) used in the assessment where available.
Date of Response: 28/08/2026
View Response: 11742.pdf
Freedom of Information Request Reference: 11741
Date Received: 20/07/2026
Summary:
Please provide the following information relating to NHS Lothian’s Adult Neurodevelopmental Assessment Service: 1. The total number of adults currently waiting for a first Adult Neurodevelopmental Assessment. 2. The referral month and year currently being offered first assessment appointments. 3. The current median waiting time from referral acceptance to first assessment. 4. The number of patients referred in October 2024 who are still waiting for their first assessment.
Date of Response: 28/08/2026
View Response: 11741.pdf
Freedom of Information Request Reference: 11740
Date Received: 17/07/2026
Summary:
Q1. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) • Myelofibrosis (ICD10 code D47.4) • Polycythaemia Vera (ICD10 code D45) • Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005) Q2. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) • Momelotinib • Fedratinib Q3. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with? • Hydroxycarbamide • Interferon therapy Q4. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy (First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.) Treatment First systemic therapy Received prior systemic therapy Ruxolitinib (Jakavi) Fedratinib (Inrebic) Momelotinib (Omjjara)
Date of Response: 20/08/2026
View Response: 11740.pdf
Freedom of Information Request Reference: 11738
Date Received: 17/07/2026
Summary:
Please provide the following information relating to NHS Lothian GP practices and shared care arrangements with private providers: 1. Any current NHS Lothian policy, guidance or standard operating procedures relating to NHS GP practices entering into shared care arrangements with private specialists. 2. Any communications, circulars or advice issued to GP practices since 1 January 2022 concerning shared care with private providers. 3. Whether NHS Lothian maintains any record of which GP practices currently participate in shared care arrangements with private specialists. 4. If such records are held: o the number of GP practices currently participating; o the number declining all such arrangements; and o any criteria or guidance used to determine eligibility. 5. Any Equality Impact Assessment, service review, audit or report considering variation between GP practices in accepting shared care arrangements. 6. Any documents discussing or assessing variation in patient access to shared care between GP practices within NHS Lothian.
Date of Response: 18/08/2026
View Response: 11738.pdf
Freedom of Information Request Reference: 11737
Date Received: 17/07/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available? Name of medicine 1.1 Acalabrutinib (Calquence) 1.2 Ibrutinib (Imbruvica) 1.3 Pirtobrutinib (Jaypirca) 1.4 Venetoclax (Venclyxto) 1.5 Zanubrutinib (Brukinsa) 1.6 Rituximab 1.7 Obinutuzumab (Gazyvaro) Q2. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available? Name of medicine 2.1 Acalabrutinib (Calquence) 2.2 Ibrutinib (Imbruvica) 2.3 Pirtobrutinib (Jaypirca) 2.4 Venetoclax (Venclyxto) 2.5 Zanubrutinib (Brukinsa) 2.6 Obinutuzumab (Gazyvaro) 2.7 Rituximab Q3. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available? Name of monotherapy or combination 3.1 Acalabrutinib 3.2 Ibrutinib 3.3 Zanubrutinib 3.4 Pirtobrutinib 3.5 Bortezomib 3.6 Lenalidomide Q4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as combination or monotherapy in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available? Combination Acronym 4.1 Ibrutinib + Venetoclax I+V 4.2 Obinutuzumab + Venetoclax V+O 4.3 Venetoclax + Rituximab V+R 4.4 Rituximab + Fludarabine + Cyclophosphamide R-FC 4.5 Rituximab + R-CHOP R-CHOP 4.6 Rituximab + Bendamustine R-Benda 4.7 Rituximab + Chlorambucil R-Chlor 4.8 Obinutuzumab + Chlorambucil O-Chlor 4.9 Acalabrutinib + Venetoclax +/- Obinutuzumab Q5. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?   Name of medicine  5.1 Azacitidine  5.2 Cytarabine  5.3 Venetoclax (Venclyxto)  Q6. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?  Name of combination  6.1 Venetoclax + Azacitidine (with or without posaconazole)  6.2 Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C) 
Date of Response: 20/08/2026
View Response: 11737.pdf
Freedom of Information Request Reference: 11736
Date Received: 17/07/2026
Summary:
My request concerns ophthalmology services commissioned, referred or otherwise funded by your Health Board and delivered by independent (non-NHS) providers. Where a provider not named below has delivered NHS-funded ophthalmology work for your Board, please include them and identify them by name. Cataract Surgery is my lead / primary interest; please prioritise this element if any part of the request must be handled separately.
Date of Response: 18/08/2026
View Response: 11736.pdf
Freedom of Information Request Reference: 11734
Date Received: 17/07/2026
Summary:
In relation to the recently launched Obesity Pathway Innovation Programme (OPIP) pilot of which your organisation is the host. A. Service model and scope 1. A copy of the project description or service specification submitted as part of the OPIP application, or any equivalent document describing the service model to be delivered. 2. The total number of patients the project aims to support over its duration, disaggregated by year where available. 3. The clinical pathways or referral routes that patients can use to access the project. 4. The range of weight management interventions available within the project, including: 1. lifestyle and behavioural support; 2. digital tools or platforms; 3. pharmacotherapy obesity treatments (including which medicines, where clinically appropriate); and 4. specialist clinical care. B. Delivery arrangements and providers 1. A list of all organisations (including NHS bodies, independent sector providers, third sector organisations, and technology or platform suppliers) involved in delivering or supporting the project, and a brief description of the role each plays. 2. Details of any contracts, grant agreements, or service level agreements entered into with non-NHS providers for the purpose of delivering this project, including the name of the provider, the nature of the service commissioned, and the contract value or funding amount where this has been determined. C. Governance and funding 1. The total value of OPIP grant funding allocated to your project, including the split between government and Lilly funding where this has been specified. 2. Details of the governance or oversight arrangements for the project, including the lead clinical or operational lead (name and position where possible) and any project board or steering group. 3. Details of any plans to publish findings, data, or service evaluation reports arising from this project, including: 1. the anticipated timeline for interim and final reporting; 2. the bodies responsible for publishing or disseminating results (for example, Innovate UK, NHS England, or the host commissioner); and 3. whether a formal evaluation framework or learning methodology has been agreed as a condition of the grant funding.
Date of Response: 25/08/2026
View Response: 11734.pdf
Freedom of Information Request Reference: 11732
Date Received: 17/07/2026
Summary:
Please provide all relevant materials covering transgender information for children and teenagers. Please also provide details about how the materials were developed and commissioned and copies of minutes relating to this including relevant committees and scrutiny boards.
Date of Response: 20/08/2026
View Response: 11732.pdf
Freedom of Information Request Reference: 11730
Date Received: 17/07/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and the end of June 2026, or latest 3-month period available? 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Capivasertib (Truqap) 1.4 Elacestrant (Orserdu) 1.5 Fulvestrant (fulvestrant or Faslodex) 1.6 Inavolisib (Inaqovi) 1.7 Imlunestrant (Inluriyo) 1.8 Olaparib (Lynparza) 1.9 Palbociclib (Ibrance) 1.10 Ribociclib (Kisqali) 1.11 Talazoparib (Talzenna) 1.12 Trastuzumab Deruxtecan (Enhertu) 1.13 Vepdegestrant (Veppanu) Q2. How many patients were treated in total, regardless of diagnosis, with the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 2.1 Pertuzumab (Perjeta) 2.2 Pertuzumab with Trastuzumab (Phesgo) 2.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 2.4 Trastuzumab Deruxtecan (Enhertu) 2.5 Trastuzumab Emtansine (Kadcyla) 2.6 Tucatinib (Tukysa) 2.7 Neratinib (Nerlynx) Q3. How many patients were treated specifically for breast cancer (ICD-10 codes = C50*, D509) in the 3 months between the start of April 2026 and the end of June 2026? 3.1 Olaparib - All types of breast cancer 3.2 Olaparib - Locally advanced or metastatic breast cancer 3.3 Talazoparib – All types of breast cancer 3.4 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) - All types of breast cancer 3.5 Trastuzumab Deruxtecan (Enhertu) - All types of breast cancer Q4. How many patients received the following medicines with curative treatment intent in the 3 months between the start of April 2026 and the end of June 2026, or latest 3-month period for which data are available? 4.1 Abemaciclib (Verzenios) 4.2 Ribociclib (Kisqali) 4.3 Pertuzumab (Perjeta) 4.4 Pertuzumab with Trastuzumab (Phesgo) 4.5 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) 4.6 Trastuzumab Emtansine (Kadcyla) Q5. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period for which data are available? 5.1 Pertuzumab (Perjeta) 5.2 Pertuzumab with Trastuzumab (Phesgo) 5.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 5.4 Trastuzumab Emtansine (Kadcyla) Q6. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period for which data are available? 6.1 HER2+ve Breast Cancer 6.2 HER2-low Breast Cancer Q7. How many patients were treated with the following medicines in combination in the 3 months between the start of April 2026 and the end of June 2026, or latest 3-month period available? 7.1 Pertuzumab + Trastuzumab (Phesgo) + Taxane (Docetaxel or Paclitaxel) 7.2 Pertuzumab (Perjeta) + Trastuzumab Deruxtecan (Enhertu)
Date of Response: 18/08/2026
View Response: 11730.pdf
Freedom of Information Request Reference: 11729
Date Received: 16/07/2026
Summary:
Please provide the NHS board's expenditure on: • Agency staff; and • Overtime payments, for each financial year from 2020-21 to 2025-26, together with any expenditure recorded for 2026-27 up to the date of this request. Please provide a breakdown by: • Financial year. • Council service or department.
Date of Response: 18/08/2026
View Response: 11729.pdf
Freedom of Information Request Reference: 11728
Date Received: 16/07/2026
Summary:
1. Please could you provide the name and email for the following job roles withing your organisation, as of March June 2026: a) Chief Operating Officer b) Deputy Chief Operating Officer c) Director of Performance d) Director of Operations e) Associate/deputy Director of Operations 2. Please could you provide the names and email addresses for the following, within the following specialities: General Surgery : General Manager: Service Manager: Urology General Manager: Service Manager: Trauma & Orthopaedics General Manager: Service Manager: ENT General Manager: Service Manager: Ophthalmology General Manager: Service Manager: Dermatology General Manager: Service Manager: Cardiology General Manager: Service Manager: Radiology General Manager: Service Manager: Pain Management General Manager: Service Manager: Gynaecology General Manager: Service Manager: Pathology General Manager: Service Manager: 3. Has the Trust utilised the services of an Insourcing Company (utilising Insourced clinical staff within Trust facilities to undertake additional activity) – within the Financial Year 2024/2025 and 2025/26 if you have them? 4. Which specialties has the Trust utilised Insourcing for within the Financial Year 2024/2025 and 2025/26 (if you have them) and the spend in each of those specialties? 5. Which specialties has the Trust utilised Outsourcing for within the Financial Year 2024/2025 and 2025/26 and the spend in each of those specialties?
Date of Response: 18/08/2026
View Response: 11728.pdf
Freedom of Information Request Reference: 11727
Date Received: 16/07/2026
Summary:
1) How many reports of sexual assault in an NHS hospital in your health board were made in 2025-26? 2) How many reports of rape in an NHS hospital in your health board were made in 2025-26? 3) If possible, at which hospitals the reported incidents took place and how many incidents took place at each hospital, without revealing any sensitive data.
Date of Response: 20/08/2026
View Response: 11727.pdf
Freedom of Information Request Reference: 11725
Date Received: 15/07/2026
Summary:
Can you please confirm the current waiting times for a person that has been referred to Midlothian MSK Physiotherapy (from referral date to start date of physiotherapy treatment), after the person has had an MRI scan on their back and been diagnosed with multilevel degenerative lumbar spondylotic changes with disc herniations at L4/L5 and L5/S1 but no neural compression and there is evidence of early degenerative osteoporotic changes in the spine.
Date of Response: 18/08/2026
View Response: 11725.pdf
Freedom of Information Request Reference: 11724
Date Received: 15/07/2026
Summary:
I would like to request the following information relating to the healthcare capacity and planned investment for East Calder Medical Practice: 1. Current registered patient list size at East Calder Medical Practice, and projected patient list size up to 2028. 2. Current FTE GPs at East Calder Medical Practice. 3. Current floorspace/ gross internal area of East Calder Medical Practice. 4. The assessed maximum capacity of the existing East Calder Medical Practice building. 5. Any business cases, options appraisals, feasibility studies, or investment plans produced since 2021 relating to: Expansion of the existing practice; and/or a new, purpose-built health centre. 6. Current status, programme milestones, or reasons for delay (if applicable) relating to the delivery of a new or expanded healthcare facility.
Date of Response: 20/08/2026
View Response: 11724.pdf
Freedom of Information Request Reference: 11723
Date Received: 15/07/2026
Summary:
Per bulletpoint 6 https://www.publications.scot.nhs.uk/files/pca2018-m-03.pdf 1/ May I ask how many so-called Golden Hello payments for new GPs at 2C and 17C practices have been made in your board area in 2025 and 2026 to date. 2/ Can you tell me the total amount for these payments in each year.
Date of Response: 18/08/2026
View Response: 11723.pdf
Freedom of Information Request Reference: 11722
Date Received: 15/07/2026
Summary:
I would like data statistics of the reliability rste, and false positive/ false negative rates on all type of drug screenings used by GP surgeries and drug misuse clinics across NHS Lothian. In particular MELD (Mid and East Lothian drugs) located in Musselburgh, Ladywell way, EH21 6AB. I wish to be provided statistics on the accuracy of all types of toxicology screenings used by the facility. In particular I would like to know the specific brand of test used, type of tests, and data accuracy of both urine screenings and mouth-swab screenings used by this facility. I would like to know which lab is used by this facility to screen these test results and the devices/ process used by the lab/ clinic during these screenings. Furthermore, I ask to be provided any statistics on false positive/ false negative rates of both types of these tests, the overall reliability of these tests and the number of tests that are routinely sent for secondary lab confirmation. I would also like to see the official NHS clinical guidelines and protocols that should be observed when administering these screenings, alongside official protocols and guidelines of how these test results are interpreted by staff.
Date of Response: 20/08/2026
View Response: 11722.pdf
Freedom of Information Request Reference: 11721
Date Received: 14/07/2026
Summary:
In regards to the National incident response levels: guidance for health boards, please provide the following information for each calendar year from 2019 to 2026 (most recent). 1. The number of times that your health board declared a: - i. Business Continuity Incident ii. Critical Incident iii. Major Incident 2. In response to the answer to Question 1, please specify, where relevant, the i) reason for the incident being declared, ii) date(s), and iii) location (e.g. hospital, ward/department).
Date of Response: 20/08/2026
View Response: 11721.pdf
Freedom of Information Request Reference: 11719
Date Received: 14/07/2026
Summary:
In Q2 2026, the 3 months (April - June 2026), how many haemophilia A and B and von Willebrand patients were treated with the following coagulation factors in your trust and how much volume (IUs or mg) was used? Hemlibra (non-inhibitor patients) Hemgenix Altuvoct Advate Adynovi Elocta Esperoct NovoEight ReFacto AF Nuwiq Hympavzi Idelvion Refixia Alprolix BeneFIX Replenine Rixubis Veyvondi Voncento Wilate Willfact
Date of Response: 25/08/2026
View Response: 11719.pdf
Freedom of Information Request Reference: 11718
Date Received: 14/07/2026
Summary:
I would like to request the following information for Q2 2026 (April–June 2026). Please provide total volume (IU/mg) and, where available, total number of patients treated with the following products: • NovoSeven (eptacog alfa) • Cevenfacta (eptacog beta) • FEIBA (anti-inhibitor coagulant complex) • Obizur (susoctocog alfa) • Hemlibra (emicizumab) (haemophilia A inhibitor patients only) Where feasible from existing records, I would also welcome any available breakdown of these patient numbers and/or volumes by indication. For example: • haemophilia A with inhibitors • haemophilia B with inhibitors • Acquired haemophilia (AHA) • Glanzmann thrombasthenia • Factor VII deficiency • other (please specify) Partial breakdowns (e.g. for only some indications) are welcome.
Date of Response: 25/08/2026
View Response: 11718.pdf
Freedom of Information Request Reference: 11717
Date Received: 14/07/2026
Summary:
For your children and young people’s speech and language therapy service: 1. The longest waiting time for initial contact* for children and young people’s speech and language therapy on 1st May 2026 (or as close to this date as possible). 2. On 1st May 2026, please tell us how many people were waiting for initial contact* for children and young people’s speech and language therapy. Please break this down by numbers waiting: - Less than 12 weeks - 12 to 18 weeks - 19 weeks to 26 weeks - 27 weeks to 52 weeks - 1 year to 2 years - Over two years 3. The longest wait for individualised therapy on 1st May 2026. 4. Please detail the health substantive core funding committed for children and young people’s speech and language therapy for the current business year – 2026/27. 5. Please detail the external funding committed for children and young people’s speech and language therapy for the current business year – 2026/27. List by type of funding, i.e. core service level agreement(s) with relevant local authorities, attainment challenge, early years, pupil equity fund, 3rd Sector etc. 6. Please confirm the number of whole time equivalent (WTE) speech and language therapists employed in the children’s speech and language therapy service as of 1st May 2026. 7. In addition, please confirm the headcount of qualified speech and language therapists (i.e. individual staff members, regardless of WTE) working in the same service during that period. 8. Please confirm how many whole time equivalent (WTE) speech and language therapist assistants were employed in the children’s speech and language therapy service on 1st May 2026. 9. In addition, please confirm the headcount of speech and language therapy assistants (i.e. individual staff members, regardless of WTE) working in the same service during that period.
Date of Response: 18/08/2026
View Response: 11717.pdf
Freedom of Information Request Reference: 11716
Date Received: 09/07/2026
Summary:
• The mean waiting times for a first consultation for a hip replacement in NHS Lothian. • The longest waiting time for a first consultation for a hip replacement in NHS Lothian. • What criteria NHS Lothian applies when deciding how urgent a patient’s need for a hip replacement is, including any assessment of ongoing pain and pain management. • What actions are being taken by NHS Lothian to address severely long waiting times in orthopaedics, including for hip replacement.
Date of Response: 20/08/2026
View Response: 11716.pdf
Freedom of Information Request Reference: 11715
Date Received: 14/07/2026
Summary:
Adult Community Service Community Definition: Outpatient speech and language therapy services in community settings (i.e. not outpatient services delivered within an acute setting), domiciliary, community hospitals, care homes etc. 1. How many adults were waiting for initial contact on 1st May 2025 and 1st May 2026*. Please break this down by how many were waiting: i. Less than 12 weeks ii. 12 to 18 weeks iii. 19 weeks to 26 weeks iv. 27 weeks to 52 weeks v. 1 year to 2 years vi. over two years 2. The longest waiting time for initial contact for adults speech and language therapy on 1st May 2025 and 1st May 2026. 3. What was the overall budget for the community adult speech and language therapy service in the financial years 2025/2026 and 2026/2027. 4. Please confirm how many whole time equivalent (WTE) speech and language therapists were employed in the community adult service on 1st May 2025 and 1st May 2026. 5. In addition, please confirm the headcount of qualified speech and language therapists (i.e. individual staff members, regardless of WTE) working in the same service during that period. 6. Please confirm how many whole time equivalent (WTE) speech and language therapist assistants were employed in the community adult service on 1st May 2025 and 1st May 2026 7. In addition, please confirm the headcount of speech and language therapy assistants (i.e. individual staff members, regardless of WTE) working in the same service during that period. Adult Learning Disability Service (ALD) ALD Definition: Speech and language therapy services designed to support Adults with a Learning Disability. If you are unable to split your recorded data by ALD and community, please indicate the proportion of time and resource spent on each. 1. How many adults were waiting for initial contact on 1st May 2025 and 1st May 2026*. Please break this down by how many were waiting: i. Less than 12 weeks ii. 12 to 18 weeks iii. 19 weeks to 26 weeks iv. 27 weeks to 52 weeks v. 1 year to 2 years vi. over two years 2. The longest waiting time for initial contact for ALD speech and language therapy on 1st May 2025 and 1st May 2026. 3. What was the overall budget for the ALD speech and language therapy service in the financial years 2025/2026 and 2026/2027. 4. Please confirm how many whole time equivalent (WTE) speech and language therapists were employed in the SLT ALD service on 1st May 2025 and 1st May 2026. 5. In addition, please confirm the headcount of qualified speech and language therapists (i.e. individual staff members, regardless of WTE) working in the same service during that period. 6. Please confirm how many whole time equivalent (WTE) speech and language therapist assistants were employed in the SLT ALD service on 1st May 2025 and 1st May 2026 7. In addition, please confirm the headcount of speech and language therapy assistants (i.e. individual staff members, regardless of WTE) working in the same service during that period. Adult Acute Service Acute Definition: Inpatient services in the acute setting and outpatient services, where the service is delivered within the acute setting. 1. How many adults were waiting for initial contact on 1st May 2025 and 1st May 2026*. Please break this down by how many were waiting: i. Less than 12 weeks ii. 12 to 18 weeks iii. 19 weeks to 26 weeks iv. 27 weeks to 52 weeks v. 1 year to 2 years vi. over two years 2. The longest waiting time for initial contact for adult acute speech and language therapy on 1st May 2025 and 1st May 2026. 3. What was the overall budget for the adult acute speech and language therapy service in the financial years 2025/2026 and 2026/2027. 4. Please confirm how many whole time equivalent (WTE) speech and language therapists were employed in the adult acute SLT service on 1st May 2025 and 1st May 2026. 5. In addition, please confirm the headcount of qualified speech and language therapists (i.e. individual staff members, regardless of WTE) working in the same service during that period. 6. Please confirm how many whole time equivalent (WTE) speech and language therapist assistants were employed in the adult acute SLT service on 1st May 2025 and 1st May 2026 7. In addition, please confirm the headcount of speech and language therapy assistants (i.e. individual staff members, regardless of WTE) working in the same service during that period.
Date of Response: 18/08/2026
View Response: 11715.pdf
Freedom of Information Request Reference: 11706
Date Received: 13/07/2026
Summary:
Please provide the following information for each calendar year from 2019 to 2026 (most recent): 1. the number of Category I (Major or Extreme) Adverse Events that have been recorded. 2. please provide detail, where available, on the incident/ event type, location (e.g. QEUH, Victoria Hospital, Kirkcaldy etc), specialty related to the incident/ event (e.g. Emergency Department QEUH etc).
Date of Response: 20/08/2026
View Response: 11706.pdf
Freedom of Information Request Reference: 11705
Date Received: 10/07/2026
Summary:
1. The number of instances of nurse absences due to stress, anxiety, depression or other psychiatric illness in total in the last six years. Please express this data in two ways: firstly in calendar years (2020, 2021, 2022, 2023, 2024, 2025 and 2026 so far) and financial year (2019/20, 2020/21, 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 so far). An FOI Clarification: By number of instances of absence I mean the overall number of absences recorded (which may include multiple absences taken by the same nurse several times). 2. The number of nurses by headcount who took an absence due to stress anxiety, depression, or other psychiatric illness in the last six years. Please express this data in two ways: firstly in calendar years (2020, 2021, 2022, 2023, 2024, 2025 and 2026 so far) and financial year (2019/20, 2020/21, 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 so far). An FOI Clarification: This request differs from request 1 because I am asking for the number of nurses who officially took an absence NOT the number of instances of absence which may count the same officer multiple times. For example, 350 nurses may have taken an absence but there may be 472 recorded instances of absence. 3. The number of working hours lost due to nurse mental health absences broken down by the last seven financial years (2019/20, 2020/21, 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 so far).
Date of Response: 18/08/2026
View Response: 11705.pdf
Freedom of Information Request Reference: 11692
Date Received: 08/07/2026
Summary:
I wish to request, under the Freedom of Information Act, the Matched Job Report and current Job Description for the West Lothian Chief Nurse post. I also wish to know the salary band for the role and what are the responsibilities of the job. Is the West Lothian Chief Nurse part of the Senior management team implementing the NHS Lothian Nursing and Midwifery Strategic Plan 2023-2028, entitled "Connecting our 'Communities, Realising our Ambitions; Reimagining Nursing and Midwifery for NHS Lothian" After 3 years of the Plan, how is the Plan's ambition of reinvigorating our workforce and making people feel valued, respected and supported being evidenced by NHS Lothian Senior management? Please give concrete examples of NHS Lothian valuing and re-invigorating its SCPHN Specialist School Nurse staff.
Date of Response: 19/08/2026
View Response: 11692.pdf
Freedom of Information Request Reference: 11690
Date Received: 08/07/2026
Summary:
Please could you provide the below information: • What was your annual print spend for 2025? • Who is your current contracted print supplier and when does that contract expire? • Which framework do you use? • Has a decision been made yet on whether the framework(s) / contract(s) are being extended or renewed?
Date of Response: 18/08/2026
View Response: 11690.pdf
Freedom of Information Request Reference: 11685
Date Received: 07/07/2026
Summary:
Q1. How many patients were treated with the following medicines in total regardless of diagnosis in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? 1.1 Glofitamab (Columvi) monotherapy 1.2 Glofitamab (Columvi) + Gemcitabine + Oxaliplatin (Glo + GEMOX) 1.3 Epcoritamab (Tepkinly) 1.4 Tafasitamab (Minjuvi) 1.5 Lenalidomide 1.6 Daratumumab Q2. How many patients with a diagnosis of Follicular Lymphoma were treated with the following medicines, in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? 2.1 Epcoritamab (Tepkinly) Monotherapy 2.2 Epcoritamab (Tepkinly) + Rituximab + Lenalidomide (E + R2) 2.3 Rituximab + Lenalidomide (R2) 2.4 Tafasitamab (Minjuvi) + Rituximab + Lenalidomide (Tafa + R2) Q3. How many patients with a diagnosis of Multiple Myeloma were treated with the following medicines in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? 3.1 Daratumumab + Bortezomib + Thalidomide + Dexamethasone (DVTD) 3.2 Daratumumab + Lenalidomide + Dexamethasone (DRD) 3.3 Daratumumab + Bortezomib + Dexamethasone (DVD) 3.4 Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRD) 3.5 Daratumumab Monotherapy 3.6 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone (IVRD) 3.7 Isatuximab + Pomalidomide + Dexamethasone (IPD) 3.8 Isatuximab + Carfilzomib + Dexamethasone (IKD) 3.9 Belantamab mafodotin Monotherapy 3.10 Belantamab mafodotin + Bortezomib + Dexamethasone (BVD) 3.11 Belantamab mafodotin + Pomalidomide + Dexamethasone (BPD) 3.12 Lenalidomide + Dexamethasone (RD) 3.13 Lenalidomide Maintenance Monotherapy Q4. How many patients with the following types of Myeloproliferative Disease were treated with the following medicines, in the 3 months between the start of April 2026 to the end of June 2026, or latest 3-month period available? Name of medicine All Types of Myeloproliferative Disease Myelofibrosis Polycythaemia Vera Essential Thrombocythaemia 4.1 Fedratinib (Inrebic) 4.2 Momelotinib (Omjjara) 4.3 Peginterferon Alfa-2a (Pegasys) 4.4 Ropeginterferon Alfa-2b (Besremi) 4.5 Ruxolitinib (Jakavi)
Date of Response: 18/08/2026
View Response: 11685.pdf
Freedom of Information Request Reference: 11675
Date Received: 06/07/2026
Summary:
I would be grateful if you could provide copies of any current policies, guidelines, standard operating procedures, admission protocols, or clinical pathways relating to pregnancy testing within your adult mental health services. Specifically, I would be appreciate copies of any documents that address: Pregnancy testing (urine or serum hCG) for women of reproductive age admitted to adult psychiatric inpatient wards. Pregnancy testing during emergency psychiatric assessment, psychiatric liaison, crisis resolution, or health-based places of safety. Physical health admission assessment protocols that include pregnancy status or pregnancy testing. Guidance relating to pregnancy testing prior to prescribing psychotropic medications (for example, valproate, lithium, or other medications where pregnancy status may influence prescribing). Any admission checklists or clerking proformas that include documentation of pregnancy status or pregnancy testing.
Date of Response: 18/08/2026
View Response: 11675.pdf
Freedom of Information Request Reference: 11655
Date Received: 01/07/2026
Summary:
1. Please confirm if you have a completed an annual inspection of any Reinforced Autoclaved Aerated Concrete (RAAC) found present in your estate 2. If the answer to question one is yes, please provide a copy of the findings of that inspection. 3. Where an inspection has been carried out, please indicate whether any RAAC which was previously categorised as green risk rating, has now been categorised as red or amber risk rating. 4. Please confirm what work, if any, has been carried out on any RAAC that have been marked by surveyors previously as at red or amber risk, or has now been upgraded 5. If you have carried out work as indicated in question 4, please a) provide a copy of any costings and b)confirm if funds to carry out work where found from within existing budgets or if extra funding was provided by the Scottish Government 6. If you have not carried out work but need to, please confirm the reasons as to why this work has not yet been carried out.
Date of Response: 18/08/2026
View Response: 11655.pdf
Freedom of Information Request Reference: 11601
Date Received: 18/06/2026
Summary:
For each financial year from 2020/21 to the most recent year available: 1. Please state whether the Board operates any of the following services: • Birth trauma service • Birth reflections service • Birth afterthoughts service • Specialist maternity psychology service • Postnatal PTSD service 2. For each service identified above, please provide: • Annual referral numbers • Average waiting times • Number of staff assigned to the service (whole-time equivalent, where available) 3. If the Board does not operate any of the above services, please confirm what support is available to women experiencing birth trauma or PTSD following childbirth.
Date of Response: 20/08/2026
View Response: 11601.pdf
Freedom of Information Request Reference: 11445
Date Received: 29/04/2026
Summary:
Under the Freedom of Information Act, please can you provide information on the following medical device: The number of bladder scanners in use within the NHS Lothian Health Board Make and model breakdown Year of purchase breakdown Hospital or site level distribution Warranty length Whether on a maintenance contract and expiry date Does the Health board service/maintain their own bladder scanners?
Date of Response: 16/06/2026
View Response: 11445.pdf
Freedom of Information Request Reference: 11430
Date Received: 27/04/2026
Summary:
1. Does the Health Board utilize disposable circular stapling anastomat devices (e.g., ZSR, CircCurer, or generic automated stapling equivalents) for adult therapeutic procedures? 2. If yes, please specify the preferred mechanism of the device used (e.g., pistol-grip or dual-handle/scissor-grip construction). 3. What is the average theatre time allocated for a traditional hand-sutured procedure versus an automated stapler procedure for adult patients? 4. Are these procedures performed in a Day Case unit/community setting or a Main Operating Theatre under general anesthesia? 5. In accordance with the Montgomery v Lanarkshire (2015) ruling, does the Board provide information to adult patients on the choice between traditional freehand surgery and automated stapling alternatives?
Date of Response: 16/06/2026
View Response: 11430.pdf
Freedom of Information Request Reference: 11444
Date Received: 28/04/2026
Summary:
I would be grateful if you could please provide the following: NHS Lothian policies, procedures etc on (a) small gestational age fetuses, (b) reduced fetal movements and (c) bereavement guidance for stillbirth and; Details on Royal Infirmary of Edinburgh bereavement suite within the maternity ward.
Date of Response: 20/08/2026
View Response: 11444.pdf
Freedom of Information Request Reference: 11739
Date Received: 17/07/2026
Summary:
We would be grateful if you could provide the following information relating to your Trust's or Health Board's Pathology services: 1. Which hospitals are part of your Trust or Health Board? 2. Which of these hospitals have Pathology Laboratories? 3. Which National Pathology Network does your organisation belong to? 4. Does your Pathology service operate in partnership with any other NHS Trusts or laboratories? If yes, please provide details. 5. What Laboratory Information Management System (LIMS/LIS) is currently used by your Pathology service? Please include the supplier and product name where possible. 6. Is your LIMS/LIS deployed as: o A single-site instance o A Trust-wide solution o A Pathology Network-wide solution o Other (please specify) 7. When is the current LIMS/LIS contract due to expire? If known, please also provide any extension options. 8. Do you operate Blood Transfusion Laboratories? If so, at which hospital sites? 9. Do you currently use an Electronic Blood Tracking solution? If yes, please state the supplier and product name. 10. Do you use a dedicated Transfusion Laboratory Information Management System (LIMS/LIS)? If yes, please state the supplier and product name. 11. Is there an individual or team responsible for leading Digital Transformation within Pathology or Diagnostics? If possible, please provide Name (where this is publicly disclosable under the FOI Act) Job title Department
Date of Response: 11/08/2026
View Response: 11739.pdf
Freedom of Information Request Reference: 11731
Date Received: 17/07/2026
Summary:
Please can you provide the amount of money (if any) your organisation has spent on legal fees related to disputes (formal or informal) in PFI contracts, for the financial years 2024/25 and 2025/6 (separated out into each year).
Date of Response: 12/08/2026
View Response: 11731.pdf
Freedom of Information Request Reference: 11713
Date Received: 15/07/2026
Summary:
Review request of the handling of 11592.
Date of Response: 03/08/2026
View Response: 11713.pdf
Freedom of Information Request Reference: 11712
Date Received: 14/07/2026
Summary:
Please can you provide a breakdown of the following for each of the past five financial years, broken down by year, including 2026-2027 to date. 1. How many incidents of vandalism have been recorded at health board-owned properties including hospitals, clinics 2. Which type of vandalism was recorded for each incident, where practical. 3. How much money has been spent on repairs for the incidents in total each year.
Date of Response: 12/08/2026
View Response: 11712.pdf
Freedom of Information Request Reference: 11710
Date Received: 14/07/2026
Summary:
Can you tell me how many people have been treated for gambling related harm by your health board in each of these years (2021-2025), using financial years if that’s how data is recorded.
Date of Response: 11/08/2026
View Response: 11710.pdf
Freedom of Information Request Reference: 11708
Date Received: 13/07/2026
Summary:
1. How long are patients having to wait to have an IUS contraceptive device fitted? 2. How long are patients having to wait to have an IUD contraceptive device fitted? 3. How long are patients having to wait to have a gynaecology appointment?
Date of Response: 11/08/2026
View Response: 11708.pdf
Freedom of Information Request Reference: 11707
Date Received: 13/07/2026
Summary:
Q1. How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib Mirvetuximab soravtansine Q2. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.
Date of Response: 11/08/2026
View Response: 11707.pdf
Freedom of Information Request Reference: 11704
Date Received: 09/07/2026
Summary:
Q1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) + Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Lenvatinib + Pembrolizumab (Keytruda + Lenvima) • Pembrolizumab monotherapy (Keytruda) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Durvalumab with Platinum-based Chemotherapy • Pembrolizumab with Platinum-based Chemotherapy • Any other SACT • If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy Q2. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) + Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Durvalumab with Platinum-based Chemotherapy • Pembrolizumab with Platinum-based Chemotherapy • Any other SACT • If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for first line Endometrial cancer Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Date of Response: 07/08/2026
View Response: 11704.pdf
Freedom of Information Request Reference: 11698
Date Received: 09/07/2026
Summary:
Please include the following information: • Whether any events have been organised for Pride month. If so please provide the date, start and end time, and title/topic of the event • Whether any LGBT themed merchandise has been purchased for Pride month. i.e. since the beginning of the 2026/27 financial year. If so please provide me with information on what has been purchased and the cost • Whether the organisation has sponsored any Pride events. If so which events and please provide details of the nature of the sponsorship (particularly the financial value)
Date of Response: 07/08/2026
View Response: 11698.pdf
Freedom of Information Request Reference: 11697
Date Received: 08/07/2026
Summary:
Please could you provide the following information for all MRI scanners currently operated by, or used by, your organisation: 1. The hospital/site where each MRI scanner is located. 2. The number of MRI scanners at each hospital/site. 3. Whether each scanner is fixed, mobile or operated through a managed/third-party service. 4. The manufacturer and model of each scanner, where available. 5. Whether each scanner is a conventional helium-cooled system, low-helium system, zero boil-off / helium-recirculating system, or helium-free system, where known. 6. The number of MRI scans/examinations carried out in the latest available year, broken down by hospital/site if available.
Date of Response: 06/08/2026
View Response: 11697.pdf
Freedom of Information Request Reference: 11696
Date Received: 08/07/2026
Summary:
1. Please provide the number of patients, who were admitted with a stroke that received thrombectomy treatment in a) 2021/22, b) 2022/23, c) 2023/24, d) 2024/25, e) 2025/26 2. Please provide the number of patients, who were admitted with a stroke that did not receive thrombectomy treatment in a) 2021/22, b) 2022/23, c) 2023/24, d) 2024/25, e) 2025/26 3. Please provide the number of days, on average, those who receive thrombectomy treatment spend in hospital post-treatment in comparison to the number of days spent, on average, in hospital by those who don’t receive thrombectomy treatment.
Date of Response: 11/08/2026
View Response: 11696.pdf
Freedom of Information Request Reference: 11694
Date Received: 08/07/2026
Summary:
The longest recorded wait (in days or weeks) for a person to begin CAMHS treatment after referral. By longest wait I mean the longest wait (in days) that an individual had out of everyone who had waited to begin CAMHS treatment. Please provide the longest wait per year for the last six years (2021, 2022, 2023, 2024, 2025 and 2026). Please provide this information in a very clear way and state the number of weeks or days very clearly.
Date of Response: 05/08/2026
View Response: 11694.pdf
Freedom of Information Request Reference: 11693
Date Received: 08/07/2026
Summary:
I would like to request information relating to reported incidents of violence and aggression within Emergency Departments (EDs) operated by the Trust. Please provide the following information for each ED site managed by the Board, broken down by month, between January 2018 and May 2026: 1. Please provide the total number of reported incidents involving violence, aggression, or abusive behaviour in Emergency Departments 2. Where available, please separately categorise [LO1] incidents by type, including: o Verbal abuse o threats of violence o physical assault o sexual harassment o discrimination-based abuse (because of: age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion and belief, sexual orientation
Date of Response: 12/08/2026
View Response: 11693.pdf
Freedom of Information Request Reference: 11691
Date Received: 07/07/2026
Summary:
Gastric and Gastro-oesophageal Junction (GOJ) Adenocarcinoma – Data Request (Last 12 Months) 1. How many patients have been diagnosed with locally advanced unresectable or metastatic gastric adenocarcinoma in your Trust in the last 12 months? 2. How many patients have been diagnosed with locally advanced unresectable or metastatic gastroesophageal junction (GOJ) adenocarcinoma in your Trust in the last 12 months? 3. Of the patients from Questions 1 and 2 (locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma), how many have been treated with each of the following regimens in your Trust? a. Zolbetuximab + chemotherapy b. Pembrolizumab + chemotherapy c. Nivolumab + chemotherapy d. Paclitaxel + ramucirumab e. Other chemotherapy (including but not limited to FLOT, FOLFOX, CAPOX, ECX, FOLFIRI f. Best supportive care
Date of Response: 05/08/2026
View Response: 11691.pdf
Freedom of Information Request Reference: 11688
Date Received: 08/07/2026
Summary:
please provide the following information relating to all insourcing contracts, insourcing providers, or waiting-list initiative services used by your organisation from 1 January 2024 to the present. For each provider, please provide: 1. Provider name. 2. Specialty or specialties covered. 3. Hospital/site where the work was undertaken. 4. Contract start date and end date. 5. Total contract value. 6. Total amount paid to date. 7. Whether the contract was awarded via a framework agreement, direct award, or competitive tender. 8. Name of the framework used (if applicable). 9. Procurement reference number or contract reference. 10. Number of insourcing weekends, sessions, or programmes delivered. 11. Total number of patients treated. 12. Total number of procedures, clinics, or diagnostic tests undertaken. 13. Any agreed activity targets and whether they were achieved. Please also provide the rates charged by the provider, including (where held): Daily rates. Sessional rates. Theatre list rates. Per patient rates. Per procedure rates. Hourly rates. Weekend or out-of-hours premiums. Rates for consultants. Rates for surgeons. Rates for anaesthetists. Rates for nurses. Rates for operating department practitioners (ODPs). Rates for healthcare assistants. Rates for radiographers, endoscopists or other clinical staff supplied. Management fees. Administration fees. Mobilisation charges. Equipment charges. Consumable charges. Travel or accommodation charges. For each contract, please also provide: A copy of the pricing schedule or rate card (with only genuinely exempt information redacted if necessary). A copy of the contract award notice or contract. The service specification. Key performance indicators (KPIs). Performance reports or contract review reports. Any penalties, service credits, or contractual deductions applied. Whether any contract extensions or variations have been agreed.
Date of Response: 07/08/2026
View Response: 11688.pdf
Freedom of Information Request Reference: 11687
Date Received: 07/07/2026
Summary:
Please could you send me a copy of (or link to) any current policies relating to adult weight management services (all tiers, including policies governing access criteria to surgery or drugs for weight management) AND copies of any equality impact assessments carried out in relation to those policies (including in respect of the Equality Act Public Sector Equality Duty and the Fairer Scotland/Socio-Economic Duty?)
Date of Response: 05/08/2026
View Response: 11687.pdf
Freedom of Information Request Reference: 11686
Date Received: 07/07/2026
Summary:
Q1. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: Atezolizumab (Tecentriq) Avelumab (Bavencio) Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Nivolumab (Opdivo) Cisplatin with Gemcitabine + Avelumab (Bavencio) Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev) Pembrolizumab (Keytruda) monotherapy Nivolumab (Opdivo) Other active systemic anti-cancer therapy Palliative care only Erdafitinib Cisplatin + Gemcitabine + Durvalumab (Imfinzi) BCG therapy Chemo-Radiation Therapy Q2. In the Metastatic urothelial cancer setting only, how many patients in the past 3 months were treated with the following systemic anti-cancer therapies first line approaches? Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Avelumab (Bavencio) Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev) Pembrolizumab (Keytruda) monotherapy Atezolizumab (Tecentriq) monotherapy Palliative care only Other
Date of Response: 05/08/2026
View Response: 11686.pdf
Freedom of Information Request Reference: 11682
Date Received: 07/07/2026
Summary:
Further to your response to your reply I received yesterday I have reviewed the Model Code of Conduct as you have outlined. I would be grateful if you could direct me where in the aforementioned document it states dealing with a complaint at a local level is discretionary. Stating that it is discretionary in formal communication is factually inaccurate. Furthermore, information received from the prescribed person ESC states that public bodies will have an internal policy. I make reference to the wording.
Date of Response: 05/08/2026
View Response: 11682.pdf
Freedom of Information Request Reference: 11681
Date Received: 07/07/2026
Summary:
I ask that the review considers the following: 1. Whether section 12 was correctly applied to the whole request, or whether partial information could have been provided. 2. Whether NHS Lothian holds any centrally available information that could answer the issue in part, including but not limited to: o Staff Bank annual leave policy or procedure o Guidance issued to bank workers explaining how annual leave accrues and how it must be claimed o Any standard emails, letters, induction materials, intranet pages or BankStaff guidance on annual leave o Any payroll or BankStaff reports showing annual leave claimed, paid, accrued, expired, outstanding or unclaimed o Any audit, risk assessment, staff governance review, complaint, grievance or internal discussion about unclaimed Staff Bank annual leave o The number of bank workers who claimed annual leave in the last financial year o The total value or total hours of annual leave paid to bank workers in the last financial year o Any information explaining what happens to accrued but unclaimed leave at the end of each quarter or leave year 3. Whether NHS Lothian has complied with its duty to provide advice and assistance by explaining what narrower request could be answered within the cost limit. The Scottish Information Commissioner states that authorities have a duty to provide reasonable advice and assistance to people making, or planning to make, information requests. (foi.scot) 4. Whether the response contains an error, as it refers to reviewing “case files relating to patients”, which does not appear relevant to Staff Bank annual leave.
Date of Response: 05/08/2026
View Response: 11681.pdf
Freedom of Information Request Reference: 11679
Date Received: 07/07/2026
Summary:
I would be grateful if you could provide the following information for each calendar year from 2021 to 2026 inclusive: 1. The number of attendances at Accident and Emergency departments, Minor Injury Units or other unscheduled care services within your Health Board area where the presenting complaint, diagnosis or recorded incident involved a dog attack, dog bite or injury caused by a dog. 2. Of the attendances identified above, the number involving: a. persons aged under 16 years; b. persons aged 16 years and over. 3. The total number of inpatient admissions arising from dog attacks, dog bites or injuries caused by dogs. 4. The total number of inpatient bed days attributable to admissions arising from dog attacks, dog bites or injuries caused by dogs. 5. The average length of stay, in days, for patients admitted following a dog attack, dog bite or injury caused by a dog. 6. The number of operative procedures undertaken as a result of injuries sustained in dog attacks, dog bites or injuries caused by dogs. 7. Any recorded estimate of the cost incurred by the Health Board in treating patients following dog attacks, dog bites or injuries caused by dogs. 8. The number of patients admitted to: a. intensive care units b. high dependency units; following a dog attack, dog bite or injury caused by a dog. 9. Whether the breed or type of dog involved in an incident is routinely recorded by the Health Board. 10. If the answer above is yes, the number of incidents recorded for each breed or type of dog for the period 2021 to 2026. 11. Copies of any current policies, guidance notes, clinical protocols or data recording guidance relating to the recording, classification or reporting of dog attacks, dog bites or injuries caused by dogs.
Date of Response: 05/08/2026
View Response: 11679.pdf
Freedom of Information Request Reference: 11678
Date Received: 07/07/2026
Summary:
Review in relation to the handling of 11560.
Date of Response: 05/08/2026
View Response: 11678.pdf
Freedom of Information Request Reference: 11677
Date Received: 06/07/2026
Summary:
Q1. How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with: •CAPOX (Capecitabine with Oxaliplatin) •FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) •Lonsurf (Trifluridine - tipiracil) •Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) •Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) •Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) •Zolbetuximab (Vyloy) •Any other systemic anti-cancer therapy •Palliative care only •Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil) •Taxanes (e.g. docetaxel, paclitaxel) •Irinotecan Chemotherapy
Date of Response: 03/08/2026
View Response: 11677.pdf
Freedom of Information Request Reference: 11676
Date Received: 06/07/2026
Summary:
Could you please send me the matched job report for band 7 clinical lead in the RIE theatres and DCN theatres. There are around eight band 7 roles but I assume that there is matched job report that covers them all.
Date of Response: 03/08/2026
View Response: 11676.pdf
Freedom of Information Request Reference: 11674
Date Received: 06/07/2026
Summary:
1. What is the total number of individuals on a waiting list for an adult ADHD assessment, as of the most recent date for which figures are held? Please provide a breakdown of this total by recorded gender, where this information is held. 2. Is there an active assessment pathway and/or waiting list accepting referrals for adult ADHD assessment? If the pathway and/or waiting list is capped or restricted in any way, please specify how the cap operates and/or the restriction criteria. 3. If there is no longer an active assessment pathway or waiting list for adult ADHD assessment, please provide: (1) the date the service closed and (2) the number of individuals on the waiting list at service closure. If the number of individuals on the waiting list at service closure was ‘0’ or this data is not held, please instead provide: (1) the date of service closure, (2) the number of individuals on the waiting list 12 months before service closure, and (3) the total number of assessments carried out across the 12 months before service closure. Please also provide a breakdown of these totals (regarding the numbers of individuals) by recorded gender, where this information is held. 4. What is the total number of adult ADHD referrals received in each of the last 5 full financial years, and the year-to-date for the current financial year? Please provide a breakdown of these totals by recorded gender (of the referred individual), where this information is held. 5. What is the total number of adult ADHD assessments carried out in each of the last 5 full financial years, and the year-to-date for the current financial year? Please provide a breakdown of these totals by recorded gender (of the assessed individual), where this information is held. 6. What is the shortest and longest recorded wait, in weeks, between referral and completed assessment appointment for adult ADHD in the last 5 full financial years? 7. What is the average wait time, in weeks, between referral and completed assessment appointment for adult ADHD in each of the past 5 full financial years, and the year-to-date for the current financial year? 8. What is the longest current wait, in weeks, of any individual currently on the adult ADHD assessment waiting list (i.e. time elapsed between referral and present date where an assessment has not yet been carried out/completed)? 9. What is the total number of people currently on a waiting list to begin medication titration following an adult ADHD diagnosis, as of the most recent date for which figures are held? Please provide a breakdown of this total by recorded gender, where this information is held. 10. Are new shared care agreements for adult ADHD treatment offered by the health board? If they are, please identify how many individuals entered a shared care agreement in the last 12 months. Please provide a breakdown of this total by recorded gender, where this information is held. If they are not, please identify the date new shared care agreements stopped being offered. 11. What is the total number of individuals in each of the last 5 full financial years, and year-to-date for the current financial year, who had/have an arranged shared care agreement for adult ADHD treatment? Please provide a breakdown of each of these totals by recorded gender, where this information is held. 12. What is the total number, in each of the last 5 full financial years, of individuals referred for assessment under CAMHS who aged out of CAMHS' services before accessing their ADHD assessment? Please provide a breakdown of each of these totals by recorded gender, where this information is held. 13. Is there an available assessment pathway for adults originally referred for assessment under CAMHS but who were unable to access ADHD assessment before aging out of the service?If there is, what is the total number of individuals on a waiting list for adult ADHD assessment who were initially referred under CAMHS but aged out before assessment? Please provide figures for each of the past 5 full financial years and the year-to-date for the current financial year. Please provide a breakdown of these totals by recorded gender, where this information is held.
Date of Response: 03/08/2026
View Response: 11674.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Waverley Court
4 East Market Street
Edinburgh
EH8 8BG

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS
NHS Lothian Charity Logo
Tel: +44 (0)131 465 5850
Email: loth.charity@nhs.scot

Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate